The Study of How Long Participants Stay in the Hospital After Receiving Apixaban for a Blood Clot in the Lung
Completed
- Conditions
- Pulmonary ThromboembolismPulmonary Embolism (PE)
- Registration Number
- NCT03595891
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
A study based on a chart review of participants that presented with a sudden blood clot in the lung
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 660
Inclusion Criteria
- Adults participants at date of admission
- Primary presentation consistent with PE followed by objectively-confirmed acute PE
- Received anti-coagulation upon diagnosis of PE during study period and in receipt of anti-coagulation at discharge
Exclusion Criteria
- PE diagnosed during a hospital admission for a reason other than PE during the study period
- Patients receiving anticoagulation at the time of presentation
- Patients presenting outside the defined study period
Other protocol defined inclusion/exclusion criteria could apply
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Compare the average length of stay in secondary care 60 days
- Secondary Outcome Measures
Name Time Method Distribution of demographic data of patients admitted with a PE Baseline Demographic data will be summarized using descriptive statistics
Total length of stay, including repeat admissions During the first 30 days after presentation of PE Distribution of clinical characteristics of patients admitted with a PE Baseline Clinical characteristics will be summarized using descriptive statistics
Trial Locations
- Locations (1)
Local Institution
🇬🇧Cardiff, United Kingdom
Local Institution🇬🇧Cardiff, United Kingdom